13
Bridging the Gap From In Vitro to In Vivo Introduction to BioMAP ® Systems 1

Introduction to BioMAP® Systems

Embed Size (px)

DESCRIPTION

This is an introduction to the BioMAP® Systems technology platform from BioSeek, LLC

Citation preview

Page 1: Introduction to BioMAP® Systems

1

Bridging the Gap From In Vitro to In Vivo

Introduction to BioMAP® Systems

Page 2: Introduction to BioMAP® Systems

BioMAP® Systems Model Complex Biology

2

Page 3: Introduction to BioMAP® Systems

3

BioMAP® Technology Platform

BioMAPAssay Systems

ReferenceProfile Database

Predictive Informatics Tools

Human primary cells Disease-models

30+ systems

Biomarker responses to drugs are stored in the

database

Specialized informatics tools are used to predict

clinical outcomes

Human Biology Integrated into a Robust, Scalable Platform

Page 4: Introduction to BioMAP® Systems

Human primary cell-based assays Engineered to model complex human disease biology

BioMAP® Systems

4

Physiologically relevant assay conditions Mixtures of stimulation factors, co-cultures of cells

Complex culture conditions selected to achieve stable signaling networks that reflect in vivo tissue states

Clinically validated disease biomarkers

Quantitative and reproducible Robust readouts (proteins, mediators); standardized assays,

QMP, SOPs

Assay formats manage disease variations among donors

Validated with known drugs

Page 5: Introduction to BioMAP® Systems

LPS SAg HPNo

3C 4H

Mphg BT

HTh2HSM3C

HDF3CGFHDF3C HDFNo

HDF3CTHDFT

BF4T SM3C

BE3C BE4T

K3CT MyoF

KFNoKF3CT

Primary Human Cell Types Disease Relevance BioMAP*

Endothelial cells (EC)Th1 and Th2 inflammation, allergy, asthma, dermatitis, angiogenesis, wound healing, restenosis, atherosclerosis

EC+lymphocyte+monocytesTh1 inflammation, psoriasis, COPD fibrosis, monocyte and T cell responses

EC+Macrophages Macrophage responses, arthritis, COPD, fibrosis

B cells + T cells Immune responses

EC+Smooth Muscle Cells Vascular inflammation, restenosis, atherosclerosis

EC+Th2 blasts Allergy, asthma

FibroblastsArthritis, asthma, dermatitis, fibrosis, psoriasis, wound healing

Myofibroblasts Fibrosis, COPD, wound healing

Keratinocytes Psoriasis, dermatitis, wound healing

Keratinocytes+Fibroblasts Psoriasis, dermatitis, wound healing

Bronchial Epithelial CellsTh1 and Th2 inflammation Allergy, asthma, fibrosis, COPD

Bronchial Epithelial Cells +Fibroblasts Asthma, allergy, fibrosis, COPD

Smooth Muscle Cells Vascular inflammation, asthma, COPD, fibrosis

Current Validated BioMAP® Systems

5

Page 6: Introduction to BioMAP® Systems

BioMAP® Assay Development Pipeline

6

Innate immunity cells Neutrophils, M1 and M2 macrophages

Renal epithelial cells

Astrocytes

Hepatic cells Hepatocytes, sinusoidal endothelial cells (LSEC), stellate cells (HSC), liver

fibroblasts

Skeletal muscle cells, adipocytes, foam cells Skeletal myoblasts and myotubes

Adipocytes derived from adipose tissue derived mesenchymal stem cells

(ADMSC), mesenchymal stem cells (MSC), and preadipocytes

Foam cells derived from monocytes

Bone / joint cell types MSC and ADMSC-derived chondrocytes and osteoblasts, monocyte-

derived osteoclasts

Intestinal cells Intestinal epithelial cells and intestinal myofibroblasts

Page 7: Introduction to BioMAP® Systems

Informatics and Data Analysis

7

Optimized algorithms for profile matching and function similarity clustering (network pharmacology, systems biology)

Quantitative analysis for screening and lead optimization Potency and efficacy ranking, EC50 curves

Page 8: Introduction to BioMAP® Systems

BioMAP® Analysis of Prednisolone

8

BioMAP Systems

Readout Parameters (Biomarkers)

Cytotoxicity Readouts

Log

expr

essi

on ra

tio (D

rug/

DM

SO c

ontr

ol)

Control (no drug)

99% significance envelope

DoseResponse

Each Drug Induces a Signature ProfileProfiles retain shape over multiple concentrations

Page 9: Introduction to BioMAP® Systems

BioMAP® Analysis of Prednisolone - Clinical Validation

E-selectin

TNF-

IL-8

PGE2

IL-8MCP-1

MCP-1, IL-8, E-sel. decreaseLeukocyte recruitment

Many, e.g. Jilma et al., 2000

PGE2 decreasePain, swelling

Sebaldt et al., 1990

Collagen I & III

Collagen I, III decreaseSkin atrophy

Autio et al., 1994

MMP-1

PAI-1

SAA

PAI-1, SAA increaseCV complications

Sartori et al., 1999Fyfe et al., 1997

PAI-1

BioMAP® Profiling Can Bridge the Gap from In Vitro to In Vivo

9

Page 10: Introduction to BioMAP® Systems

MicrotubuleStabilizers

Mitochondrial ET chain

Retinoids

Hsp90

CDK

NFkB

MEK

DNAsynthesis

JNK

Proteinsynthesis

MicrotubuleDestabilizers

Estrogen R

PI-3K

Ca++

Mobilization

BioMAP® Analysis Reveals Mechanism of ActionPairwise Correlation of BioMAP Reveals Functional Similarities

mTOR

PKC Activation

p38 MAPK

HMG-CoAreductase

Calcineurin

Transcription

Mechanism of Action(On-Target)

PathwayRelationships

10

Page 11: Introduction to BioMAP® Systems

BioMAP® Reference Database

11

BioMAP database contains profiles of >2700 agents• Drugs – Clinical stage, approved, and failed

• Experimental Chemicals - Research tool compounds, environmental chemicals

• Biologics - Cytokines, factors, peptides, antibodies, soluble receptors

Page 12: Introduction to BioMAP® Systems

BioMAP® Applications

Screening and lead optimization using primary cells Phenotypic screening and Indication Discovery Screening for second-generation drugs

Biological annotation of compounds Target and compound validation in human cells Benchmarking to standard of care Safety assessment

Translational biology Specialized assays, also with patient cells, patient classification Testing drug combinations Annotation for pharmacodynamic markers 1212

Page 13: Introduction to BioMAP® Systems

Bridging the Gap From In Vitro to In Vivo

Contacts

Ellen Berg, PhD

General Manager

BioSeek, LLC

[email protected]

650-416-7621

BioSeek, LLC310 Utah, #100South San Francisco, CA 94080